Company Overview and News

19
Mesoblast Enters Into Strategic Cardiovascular Alliance for China With Tasly Pharmaceutical Group

2018-07-17 globenewswire
NEW YORK and MELBOURNE, Australia, July 17, 2018 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO) (ASX:MSB) today announced that it has entered into a strategic alliance with one of China’s largest pharmaceutical companies, Tasly Pharmaceutical Group (SHA: 600535; Tasly), for the development, manufacture and commercialization in China of Mesoblast’s allogeneic mesenchymal precursor cell (MPC) product candidates MPC-150-IM for the treatment or prevention of chronic heart failure and MPC-25-IC for the treatment or prevention of acute myocardial infarction.
MEOBF MSB MESO

24
Leading Commercial and Transactional Healthcare Executive Shawn Cline Tomasello Joins Mesoblast Board

2018-07-11 globenewswire
NEW YORK and MELBOURNE, Australia, July 11, 2018 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO) (ASX:MSB) today announced that Shawn Cline Tomasello has joined its Board of Directors. With more than 30 years’ experience in the pharmaceutical and biotech industries, Ms Tomasello brings substantial commercial and transactional experience to the Mesoblast board.
MEOBF CELGZ GILD MSB CELG MESO KITE

10
Mesoblast Enters Into US$50M Financing with Novaquest Capital for Commercial Readiness of Remestemcel-l in the Treatment of Acute Graft Versus Host Disease

2018-07-02 globenewswire
NEW YORK and MELBOURNE, Australia, July 02, 2018 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO) (ASX:MSB) today announced a US$50 million financing from NovaQuest Capital Management, L.L.C. (NovaQuest) for the continued development and commercialization of its allogeneic product candidate remestemcel-L (MSC-100-IV) for children with steroid refractory acute Graft versus Host Disease (aGVHD). NovaQuest was formed in 2000 as a strategic investment unit within Quintiles (now IQVIA), the world’s largest clinical research organization, and became an independent firm in 2010.
HTGZ MEOBF MSB HTGC MESO HTGX HTGY

4
Key Day 100 Survival Outcomes of Phase 3 Trial for Acute Graft Versus Host Disease Presented at 2018 ISSCR Annual Meeting

2018-06-21 globenewswire
NEW YORK and MELBOURNE, Australia, June 21, 2018 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO) (ASX:MSB) today announced key Day 100 survival outcomes of its Phase 3 trial for remestemcel-L, an allogeneic mesenchymal stem cell product candidate, in children with steroid refractory acute Graft Versus Host Disease (aGVHD). The results are being presented today at the 2018 annual meeting of the International Society for Stem Cell Research (ISSCR), being held in Melbourne from June 20-23.
MEOBF MSB MESO

62
U.S. Healthcare Leader Joseph R. Swedish Joins Mesoblast Board

2018-06-19 globenewswire
NEW YORK and MELBOURNE, Australia, June 19, 2018 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO) (ASX:MSB) today announced that Joseph R. Swedish has joined its Board of Directors. Mr. Swedish has more than two decades of healthcare leadership experience as the CEO for major U.S. healthcare organizations. Most recently, he has served as Executive Chairman, President and CEO of Anthem Inc., a Fortune 33 company and the leading health benefits provider in the U.
ATHTF MEOBF MSB CDW CDWHF MESO ANTM ANTX

11
Financial Results and Operational Highlights for the Third Quarter Ended March 31, 2018

2018-05-30 globenewswire
MELBOURNE, Australia and NEW YORK, May 30, 2018 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX:MSB) (Nasdaq:MESO) today announced strong financial results for the nine months ended March 31, 2018 and provided operational highlights for the third quarter ended March 31, 2018.
HTGZ MEOBF MSB HTGC MESO HTGX HTGY

66
Mesoblast Appoints New Chief Financial Officer

2018-05-30 globenewswire
MELBOURNE, Australia and NEW YORK, May 30, 2018 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX:MSB) (Nasdaq:MESO) today announced the appointment of Josh Muntner as its new Chief Financial Officer, based in New York.
MEOBF CRFX MSB MESO CFRXW CFRX

4
Mesoblast Financial Results Webcast for Quarter Ended March 31, 2018

2018-05-29 globenewswire
NEW YORK and MELBOURNE, Australia, May 29, 2018 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO) (ASX:MSB) will report financial results for the quarter ended March 31, 2018 in a webcast beginning at 6:30 pm on Wednesday, May 30, 2018 EST; 8:30 am Thursday, May 31, 2018 AEST.
MEOBF MSB MESO

6
Paradigm Biopharmaceuticals banking on near-term revenues from repurposing FDA approved drugs

2018-05-14 proactiveinvestors.com.au
Paradigm Biopharmaceuticals Ltd (ASX:PAR) is a biotechnology company focused on repurposing Pentosan Polysulfate Sodium (PPS), an FDA-approved drug with a long track record of safely treating inflammation.
MEOBF CMXHF CSL MSB PAR MESO

4
Mesoblast Phase 3 Trial Results for Acute Graft Versus Host Disease Presented at 2018 International Society for Cell and Gene Therapy Annual Meeting

2018-05-08 globenewswire
NEW YORK and MELBOURNE, Australia, May 08, 2018 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO) (ASX:MSB) today announced that results of the Phase 3 trial evaluating its product candidate MSC-100-IV (remestemcel-L) in children with steroid-refractory acute Graft versus Host Disease (aGVHD) were presented at the 2018 International Society for Cell and Gene Therapy (ISCT) plenary breakout session held in Boston last week.
MEOBF MSB MESO

0
Mesoblast Cell Therapies Featured at Vatican International Healthcare Conference

2018-05-01 globenewswire
NEW YORK and MELBOURNE, Australia, May 01, 2018 (GLOBE NEWSWIRE) -- Mesoblast’s proprietary allogeneic cell technology platform was featured at the Unite to Cure Fourth International Vatican Conference on global healthcare initiatives held in Vatican City from April 26-28, 2018.
MSB

4
Mesoblast Clinical Program Update for MPC-150-IM in Patients With Chronic Heart Failure

2018-04-18 globenewswire
NEW YORK and MELBOURNE, Australia, April 18, 2018 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO) (ASX:MSB) today provided an update on the Phase 3 and Phase 2b clinical trials of the Company's proprietary allogeneic mesenchymal precursor cell (MPC) product candidate MPC-150-IM in patients with moderate-to-severe and end-stage advanced chronic heart failure (CHF), respectively. These indications represent major unmet medical needs due to the high rates of morbidity and mortality despite existing therapies.
MEOBF MSB MESO

8
Mesoblast Phase 3 Cell Therapy Trial for Chronic Low Back Pain Completes Enrollment

2018-03-28 globenewswire
NEW YORK and MELBOURNE, Australia, March 28, 2018 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX:MSB) (Nasdaq:MESO) today announced that enrollment has completed in the Phase 3 trial evaluating a single intra-discal injection of its proprietary allogeneic mesenchymal precursor cell (MPC) product candidate MPC-06-ID in patients with chronic low back pain due to degenerative disc disease.
MEOBF MSB MESO WKL

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...